Drug Combination Shrinks Breast Cancer Metastases In Brain

Armen Hareyan's picture
Advertisement

A combination of a targeted therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

Advertisement